Xenikos B.V.

The second quarter Venture Monitor report from Pitchbook and the National Venture Capital Association noted a record level of venture capital exits totaling $165.2bn for the first half of 2019, incl

Xenikos BV of the Netherlands has been given the green light by the US Food and Drug Administration to start a Phase III trial of T-Guard, a potential practice-changing therapy for acute graft-versus

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar

George Golumbeski, who ran Celgene Corp. 's business development group during an active period of deal-making there, has left the big biotech to hang his own shingle as a life science business consul